Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Bernardo Rapoport

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

B.L. Rapoport1, J.A. Barnard-Tidy1, T. Smit2, S.J. Nayler3, C.A. Benn4

Author affiliations

  • 1 Medical Oncology, The Medical Oncology Centre of Rosebank, 2196 - Sandton/ZA
  • 2 Pharmacy, The Medical Oncology Centre of Rosebank, 2196 - Sandton/ZA
  • 3 Anatomical Pathology, Grtizman & Thatcher, 2121 - Parklands/ZA
  • 4 Surgery, Breast Care Centre of Excellence, 2121 - Parklands/ZA
More

Resources

Abstract 1449

Background

Ki-67 immunohistochemical determination is a widely used biomarker of cell proliferation in patients (pts) undergoing endocrine treatment for breast BC. The role of Ki-67 in pts undergoing neoadjuvant chemotherapy (NAC) for early BC remains controversial.

Methods

We analyzed retrospectively data on 137 patients undergoing taxane and/or anthracycline, transtuzumab based NAC. Luminal A was documented in 6 pts, Luminal B in 29 pts, Her-2 positive in 30 pts and triple negative breast cancers (TNBC) in 72 pts. Pathological complete response (pCR) was defined as the complete disappearance of the invasive cancer in the breast and absence of tumor in the axillary lymph nodes examined by axillary clearance.

Results

The pCR rate of the entire cohort was 41.6%. At 2 years 92% of pts who attained a pCR were disease free compared to 80% of pts who did not attain a pCR (log rank test p < 0.0147). On univariate analysis factors associated with higher pCR included primary tumor size (T1 68% vs. T2 41% vs. T3 or T4 0%, Chi2=20.05, p < 0.00017), nodal disease (N0 49% vs. N1 39% vs. N2 8%, p < 0.02948), ER receptor status (negative 59% vs. positive 14%, p < 0.00000), PR receptor status (negative 53% vs. positive 17%, p < 0.00002), molecular subtype (TNBC 53.4%, Her2=50% and Luminal A + B was 8.5%, p < 0.00002), Ki67 (>40=55% vs. 15-39=34% vs. <15=0%, p < 0.00060) and Stage (I = 85% vs. IIA=49% vs. IIB=36% vs. III=5%, p < 0.00006). Factors not associated with a higher pCR included age, menopausal status, extranodal spread and lympho-vascular invasion. In a logistic regression model Ki-67 as a continuous variable (p < 0.01203) and molecular subtype (p < 0.02228) retained its significance; while tumor size, stage of disease, nodal status, ER and PR loss significance.

Conclusions

Ki67 and molecular subtype (Her-2 positive disease and TNBC) are independent prognostic factors of pCR in pts with early BC undergoing NAC.

Clinical trial identification

Legal entity responsible for the study

The Medical Oncology Centre of Rosebank.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings